ACR ethics committee takes action again
The American College of Radiology issued an 80-day suspension to a radiologist in September for testifying inaccurately as an expert witness in a malpractice case. This was the fifth expert witness complaint to be resolved since the ACR began pursuing such grievances. The latest involved Dr. Harwood B. Hance of Redondo Beach, CA, who testified that actions by Dr. Jeffrey Zuckerman, a radiologist based in Fairbanks, AK, fell below the standard of care in treating a patient who eventually developed oliguric renal failure. The case was dismissed before it reached court, but Zuckerman complained to the ACR that Hance's testimony was inaccurate.
The American College of Radiology issued an 80-day suspension to a radiologist in September for testifying inaccurately as an expert witness in a malpractice case. This was the fifth expert witness complaint to be resolved since the ACR began pursuing such grievances. The latest involved Dr. Harwood B. Hance of Redondo Beach, CA, who testified that actions by Dr. Jeffrey Zuckerman, a radiologist based in Fairbanks, AK, fell below the standard of care in treating a patient who eventually developed oliguric renal failure. The case was dismissed before it reached court, but Zuckerman complained to the ACR that Hance's testimony was inaccurate.
The ACR has received 18 complaints of alleged ethics violations, 13 of which involved suspect expert testimony. The first hearing, in October 2003, concluded that the testimony in question was acceptable. In May 2004, the college censured a radiologist who testified in a mammography liability trial. In July, it expelled a neuroradiologist who had had two separate complaints lodged against him.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
